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Abstract Site-directed mutagenesis and molecular dynamics 
analysis of the 3-D model of the ale-adrenergic receptor (AR) 
were combined to identify the molecular determinants of the 
receptor involved in catecholamine binding. Our results indicate 
that the three conserved serines in the fifth transmembrane 
domain (TMD) of the ale-AR play a distinct role in 
catecholamine binding versus receptor activation. In addition to 
the amino acids D125 in TMDIII and S207 in TMDV directly 
involved in ligand binding, our findings identify a large number of 
polar residues playing an important role in the activation process 
of the CQ-AR thus providing new insights into the structure/ 
function relationship of G protein-coupled receptors. 
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1. Introduction 
The adrenergic receptors (AR) mediate the functional ef- 
fects of catecholamines like epinephrine and norepinephrine 
by coupling to several of the major signalling pathways modu- 
lated by G proteins. The AR family includes nine different 
gene products: three p (PI, Pz, p3), three a2 (%A, %B, %2> 
and three ~11 (alA, @, alo) receptor subtypes. 
Like almost all G protein-coupled receptors (GPCR), the 
AR family shares the presence of seven hydrophobic regions 
that are believed to form a bundle of a-helical transmembrane 
domains (TMD), connected by alternating intra- and extra- 
cellular hydrophilic loops. Mutational analysis of the ARs has 
revealed that the TMD contribute to the formation of the 
ligand binding pocket, whereas amino acid sequences of the 
intracellular loops appear to mediate receptor-G protein cou- 
pling [l]. 
The pharmacological heterogeneity of various AR subtypes 
must result from differences of their ligand binding pockets. 
However, identification of the interaction sites on the recep- 
tors for a wide range of synthetic agonists and antagonists 
remains a complex task. 
Several studies have focussed on the molecular interactions 
of the endogenous catecholamines, epinephrine and norepi- 
nephrine, with different AR subtypes. Epinephrine and nor- 
epinephrine contain a protonated amino group separated 
from the aromatic catechol ring by a P-hydroxylethyl chain. 
The molecular requirement for catecholamine binding to the 
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AR should include the electrostatic interaction between the 
receptor and the amino group of the ligand, hydrogen bonds 
between donor/acceptor sites of the receptor and the P-hy- 
droxyl as well as the catechol meta- and para-hydroxyl groups 
of the ligand, and finally van der Waals attractive interactions 
[2]. Mutagenesis studies of the /32- [3] and az*-AR [4] sug- 
gested that the amino group of the catecholamines makes an 
electrostatic interaction with the carboxylate side chain of an 
aspartate on TMDIII which is highly conserved in all GPCR- 
binding amine ligands. This aspartate is involved in high-affin- 
ity binding of agonists as well as antagonists at both the p2- 
and ~~A-AR. On the other hand, there is evidence that the 
catechol meta- and para-hydroxyl groups interact with serine 
residues present in TMDV of all GPCR which bind catechol- 
amines with high affinity. 
The serines of TMDV range from two to three in different 
receptors (Fig. 2) and the individual role of each has been 
assessed by site-directed mutagenesis only for few GPCR in- 
cluding the pz- [S], C~ZA- [4] and ~~A-AR [6] subtypes as well as 
dopamine Dl [7] and D2 [S] receptors. These studies have 
clearly shown that, despite their conservation, the role of in- 
dividual serines in ligand binding and/or receptor activation 
can vary among different catecholamine receptors. Thus, the 
results obtained on catecholamine interaction with one recep- 
tor cannot be directly extrapolated to another receptor sub- 
type. 
In this study, we have investigated the catecholamine bind- 
ing site of the am-AR subtype [9] combining site-directed 
mutagenesis of a large number of amino acids with molecular 
dynamics analysis of the 3-D model of the CX~B-AR bound to 
(-)-epinephrine. Our results indicate a distinct role of the 
three conserved serines in TMDV of the am-AR in catechol- 
amine binding versus receptor activation, providing striking 
evidence that the docking sites for catecholamines can differ 
even among closely related AR subtypes. 
2. Materials and methods 
2.1. Construction of mutated alB-ARs 
The cDNA encoding the hamster alB-AR [9] was mutated by poly- 
merase chain reaction-mediated mutagenesis technique using Taq 
DNA polymerase (Boehringer). The mutated DNA fragments ob- 
tained were digested with the appropriate enzymes and cloned into 
the expression vector pRK5 containing the alB-AR cDNA. Recombi- 
nant clones were isolated and sequenced by cycle sequencing using 
Exe- Pfu polymerase (Stratagene). For permanent expression in Rat- 
1 cells, the receptor cDNAs were subcloned into the pZip-Neo con- 
taining the neomycin resistance gene as previously described [lo]. 
2.2. Cell culture and transfections 
COS-7 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
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(DMEM) supplement with 10% fetal calf serum (FCS) and transfected 
with different DNAs following the DEAE-dextran method, as pre- 
viously described [9]. COS-7 cell (0.5X 106) grown in 35mm dishes 
were transfected with the DNA (2 @million of cells) encoding the 
various receptors and harvested 48 h after their transfection. For 
permanent expression, Rat cells were transfected with the pZip-Neo 
containing the neomycin resistance gene and the cDNA of the recep- 
tors using Ca2+-phosphate precipitation. Clones resistant to the anti- 
biotic G418 (300 @ml) were isolated and tested for their ability to 
bind the al-AR antagonist [1251]HEAT [lo]. 
2.3. Ligand binding 
Membrane preparations derived from cells expressing the different 
otn-ARs and ligand-binding experiments using [iz51]HEAT (DuPont, 
New England Nuclear) were performed as previously described [9,10]. 
Prazosin (10e6 M) was used to determine non-specific binding. For 
competition curves, a final [lz51]HEAT concentration of 80 pM was 
used. For saturation curve analysis, [1251]HEAT concentrations 
ranged from 10 to 500 pM. Data were analysed by computer, using 
an interactive non-linear regression program (LIGAND). 
2.4. Inositol phosphate determination 
For the determination of labelled inositol phosphates, COS-7 or 
Rat cells expressing the different ain-ARs were grown in 35-mm 
dishes and labelled with [3H]inositol (Anawa) at 3-5 pCi/ml for 15- 
18 h in inositol-free DMEM supplemented with 1% FCS. After label- 
ling, cells were stimulated for 45 min with (-)-epinephrine in the 
presence of 20 mM LiCl. Total inositol phosphates were extracted 
and separated as described in our previous studies [9,10]. 
2.5. 3-D model building of the ct~~-AR model and computational 
procedure 
The 3-D building of the receptor model and molecular dynamics 
(MD) analysis were performed as extensively described in our pre- 
vious work [ll]. The input structure of the (-)epinephrine-cLin-AR 
complex has been obtained by docking the agonist into the binding 
site of the minimized average structure of the wild-type am-AR car- 
rying the aspartate D142 in its protonated form [ll]. The input struc- 
ture was energy minimized and subjected to 150 ps of MD simula- 
tions. The structures averaged over the last 100 ps of the equilibrated 
time period of each MD simulation were then minimized. Modelling 
studies were performed with the molecular graphics package QUAN- 
TA (version 4.0; Molecular Simulations, 1990). Energy minimizations 
and MD simulations of the receptors were achieved on a HP-720 
workstation by means of the program CHARMM (version 22) [12]. 
3. Results and discussion 
3.1. Mutagenesis of the aspartate 0125 in TMDIII 
D125 of the am-AR is homologous to the aspartate on 
TMDIII of the ps- and asA-AR as well as Dl-R involved in 
the interaction with the amino group of catecholamines. Mu- 
tation of D125 to alanine totally impaired the ability of the 
am-AR to bind both agonists and antagonists. This is shown 
by the fact that COS-7 cells expressing the D125A receptor 
mutant displayed no specific [lz51]HEAT binding and no epi- 
nephrine-induced stimulation of inositol phosphate (IP) pro- 
duction. On the other hand, the expression of the D125A 
receptor was similar to that of the wild-type amAR as shown 
by the immunoprecipitation of the phosphorylated receptors 
following 32Pi labelling of transfected COS-7 cells (Fig. 1). 
These results strongly suggest that, similarly to the p2- and 
asA-AR [3,4], also in the am-AR the conserved aspartate 
D125 on TMDIII interacts with the functional amino group 
of both agonists and antagonists. 
3.2. Mutagenesis of the serines in TMDV 
S207, 208 and 211 of the am-AR are homologous to the 
cluster of two to three serines conserved in TMDV of GPCR 
which bind catecholamines with high affinity (Fig. 2). To as- 
sess the interaction of these serines with the catechol meta- 
and para-hydroxyl groups, they were mutated into alanine 
and the receptor mutants were tested for their ability to inter- 
act with ligands carrying both hydroxyl groups (epinephrine 
and norepinephrine), the meta-hydroxyl (phenylephrine) or 
the para-hydroxyl group (synephrine). All the receptors mu- 
tated at the serines of TMDV displayed expression levels sim- 
ilar to that of the wild-type am-AR. Mutations of S208 or 
S211 into alanine either individually or in combination did 
not result in any important effect on the receptor’s ability to 
bind ligands (Table 1). On the other hand, mutation of S207 
to alanine decreased the affinity of (-)- and (+)-epinephrine 
as well as that of (-)-norepinephrine of about 250-, 150- and 
350-fold, respectively, without changing that of the antagonist 
prazosin (Table 1). The affinity of phenylephrine and syne- 
phrine were decreased of lo- and 2-fold, respectively. 
To assess their activation properties, the receptor mutants 
were expressed transiently in COS-7 cells as well as perma- 
nently in Rat-l cells. Dose-response curves of (-)-epinephrine 
in Rat cells expressing the S207A receptor indicated that the 
maximal levels of IP accumulation (Rmaw) were comparable to 
that of cells expressing the wild-type am-AR, whereas its 
potency (ECss) was about lOO-fold lower in agreement with 
its reduced binding affinity (Fig. 2). Mutations of either S208 
or S211 did not impair the receptor’s ability to mediate epi- 
nephrine-induced IP accumulation. However, surprisingly the 
double mutant S208-S211 was completely impaired in its abil- 
ity to be activated by epinephrine (Table 1 and Fig. 2). 
These results indicate that the individual serines on TMDV 
play a different role in agonist binding versus receptor activa- 
tion. Whereas S207 is primarily involved in catecholamine 
binding, the integrity of at least one of S208 and S211 is a 
crucial requirement for receptor activation despite having a 
marginal role on ligand binding. Thus, the role of the serines 
in TMDV of the am-AR is strikingly different not only when 
compared to other catecholamine receptors, but also to the 
closely related ai*-AR subtype. In this receptor, only two of 
WT D125A 
MW I I +II I + ’ 
1 2 3 4 
Fig. 1. Phosphorylation of the criaAR and its mutant Dl25A. COS- 
7 cells transfected with the DNA encoding the wild-type (WT, lanes 
1 and 2) or mutated receptor (Dl25A, lanes 3 and 4) were labeled 
with 32Pi and the phosphorylated receptors were immunopreciptated 
as described in [lo]. Receptor phosphorylation was assessed in the 
absence (-) or presence (+) of PMA (Cphorbol 12-myristate 13- 
acetate). Position of the prestained molecular mass markers are indi- 
cated in kDa. 
A. Cavalli et al.IFEBS Letters 399 (1996) 9-13 
the three serines of the am-AR are conserved (Fig. 2). Recent 
studies [6] have shown that in the am-AR the serine homo- 
logous to S207 of the crin-AR is important for receptor acti- 
vation, but not for catecholamine binding. On the other hand, 
both serines present in the CL~A-AR might contribute to form 
one, but not two hydrogen bondings with the catechol ring. 
3.3. Mutagenesis of several other amino acids in the TMD 
To investigate the role of other amino acids in catechol- 
amine binding as well as agonist-induced receptor activation, 
we mutated several polar residues in different TMD of the 
ccrn-AR. For most receptor mutants the expression levels 
were not dramatically different than that of the wild-type 
am-AR with the exception of S135A which displayed very 
low levels of expression (Table 1). None of the mutations 
induced any great change in the stereospecificity of (-)- ver- 
Bovine alA 193 GYV LFSALGSFYVPL 
Hamster alB 202 F Y A L FSS LGSFY I P L 
Rat alD 182 GYA I FSSVGSFY LPM 
Hamster p2 198 A Y A I ASS1 VSFYV P L 
I 
I ??BAS 1 





Fig. 2. Top panel: Alignment of the conserved serines in TMD V 
of the bovine CL~AAR [13], hamster oinAR [9], rat oinAR [14] and 
hamster BsAR [3]. Middle panel: Total labeled inositol phosphates 
(3H-IP) were measured in Rat-l fibroblasts permanently expressing 
the wild-type amAR (WT), its single mutant S207A or its double 
mutant S208A/S211A in the absence (BAS) or presence of 10e4 M 
(-)-epinephrine (EPI) for 45 min. Receptor expression ranged from 
1 to 2 pmol/mg protein for all recepors. Bottom panel: Dose re- 
sponse of EPI to stimulate 3H-IP accumulation in Rat-l cells ex- 
pressing the wild-type amAR (WT) or its mutant S207A. 
D125 
S207 
Fig. 3. Top panel: View of the minimized average structure of the 
(-)-epinephrine-amAR complex in a direction parallel to the helix 
main-axes from the intracellular side. Bottom panel: Details of the 
interaction of (-keoineuhrine with residues D125 in TMD III and 
serines 207, 268 ‘add 211 in TMD V. Drawings were made with 
MOLSCRIPT (Kraulis, 1991). 
sus (+)-epinephrine binding to the receptor. Many of them did 
not have any important effect either on ligand binding or on 
the receptor’s ability to mediate catecholamine-induced IP 
accumulation. However, few mutations were identified having 
an effect on ligand binding and/or the activation process of 
the am-AR. In particular, as shown in Table 1, mutation of 
Y203 in TMDV into alanine induced about 30- and 90-fold 
decrease in the receptor’s binding affinity for (-)-epinephrine 
and (-)-norepinephrine, respectively, as well as a profound 
(~80%) impairment of the receptor-mediated IP response. 
On the other hand, mutation of Y338 in TMDVII into ala- 
nine resulted in about lo-, 30- and 70-fold decrease of the 
binding affinity of (-)-epinephrine, (-)-norepinephrine and 
prazosin, respectively. The IP response mediated by the 
Y338A mutant was similar, if not greater, than that of the 
wild-type am-AR. 
Two other mutants, T130A and S132A, carrying mutations 
of T130 and S132 in TMDIII, were also impaired (= 50%) in 
their IP response without any important change in their ligand 
binding properties. The S135A mutant displayed an IP re- 
sponse similar to that of the wild-type am-AR despite the 
fact that its expression levels were much lower. Thus, this 
mutant seems to be ‘hyperactive’ when compared to the 
wild-type am-AR expressed at similarly low levels (results 
not shown). 
3.4. Molecular dynamics analysis of the 
3-D (-)-epinephrine_alB-AR complex 
The results of site-directed mutagenesis have been inter- 
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preted by analysing the inter- and intramolecular interaction 
patterns involving the mutated amino acids in the 3-D model 
of the am-AR previously described [ll]. We have performed 
MD simulations of the (-)-epinephrineeainAR complex test- 
ing different combinations of distance constraints between 
S207 and the catecholic oxygens of the ligand. Finally, we 
selected the minimized average structure resulting from the 
simulations in which S207 has been constrained to act as H- 
bonding donor and acceptor for the meta- and para-hydroxyl 
groups, respectively, of the ligand. In fact, this interaction 
pattern involving S207 allows the cationic nitrogen atom of 
the ligand to perform a strong charge reinforced H-bonding 
interaction with D125 in TMDIII (Fig. 3). This interpretation 
is in agreement with the experimental findings showing that 
D125 in TMDIII is essential for both agonist and antagonist 
binding. Moreover, the constrained interaction with S207 al- 
lows the meta- and para-hydroxyl groups of epinephrine to 
perform additional hydrogen bonds with S208 and S211, re- 
spectively. The (-)-epinephrine-amAR complex is further 
stabilized by the intermolecular van der Waals attractive in- 
teractions between the ligand and several amino acids, i.e., 
W121, L181, S211, F311 and L314. 
TMDIV, respectively, and may exert a structural/functional 
role thus stabilizing the active conformation of the am-AR. 
This agrees with the experimental findings showing that the 
integrity of at least one of S208 and S211 is crucial for re- 
ceptor activation (Table 1 and Fig. 2). 
Our analysis highlights several other amino acids including 
T130, S132, S135, Y203 and Y338, which might play a role in 
preserving the receptor structure and function rather than 
directly interacting with the agonist. In the theoretical model, 
these residues mainly occupy interhelical positions away from 
the putative agonist binding site, thus performing intramolec- 
ular interactions. In particular, T130 in TMDIII interacts with 
T174 on TMDIV whereas the conserved S132 in TMDIII 
makes H-bonding interactions with both the highly conserved 
W307 in TMDVI and N340 in TMDVII. This is consistent 
with the fact that both T130A and S132A mutants are par- 
tially impaired in their activation process. 
Y203 in TMDV is rather directed towards the TMDIV, but 
it is close to the putative agonist binding site of the am-AR. 
This might explain the fact that the mutation of Y203 into 
alanine results in a decrease of receptor activation as well as in 
a modest decrease of the affinity for agonist binding. 
In conclusion, on the basis of this analysis, we propose that 
S207 makes a strong interaction with both the catecholic hy- 
droxy-groups of (-)-epinephrine. Such interaction seems to be 
the necessary step for promoting other stabilizing or function- 
ally important intermolecular interactions. This interpretation 
is in agreement with our experimental findings showing that 
the extent of decrease of binding affinity induced by mutation 
of S207 into alanine accounts for the breakage of more than 
one hydrogen bonding interaction (the disruption of a strong 
hydrogen boind is expected to result in about 20-fold reduc- 
tion of binding affinity). 
Concerning S135 in TMDIII, our MD analysis indicates 
that its role is to stabilize the interactions of the residues 
forming the ‘polar pocket’ of the receptor which plays a fun- 
damental role in the activation process of the am-AR [l 11. 
Thus, the disruption of the ‘polar pocket’ might underlie the 
complex effects resulting from the mutation of S135 into ala- 
nine, i.e., on one hand, a profound impairment of receptor 
expression and, on the other, the ‘hyperactivity’ of the S135A 
mutant which seems fully activated despite its low expression 
levels. 
The results of the MD analysis also indicate that S208 and 
S211 in TMDV are mainly directed towards the TMDVI and 
Furthermore, C306 in TMDVI is directed towards 
TMDVII acting as a ‘ridge’ filling the ‘groove’ formed by 
F339 and N340 thus stabilizing the TMDVUTMDVII pack- 
Table 1 
Ligand binding properties and IP accumulation in COS-7 cells expressing the wild-type am-AR (WT) or mutant receptors 
Receptor Expression IP levels I& of hgands 
B,, R (-)-EPI @M) (+)-EPI (FM) (-)-NE (PM) PHE (nM) SYN (PM) PRA (nM) 
(pmoumg) &?ver basal) 
WT 1.2+0.1 454f 55 
S207A 1.4f0.2 353+ 39 
S208A 0.9 f 0.05 375f 16 
S211A 1.2f0.2 306f 32 
S208AIS211A 0.7fO.l 1125 13 
C129A 0.9fO.l 472f 31 
T130A 0.9fO.l 1585 29 
S132A 1.1 fO.l 1712 52 
S135A 0.1 + 0.01 312f 37 
S140A 1.1 kO.3 520f 63 
S173A 1.4f0.04 568 f 100 
Sl77A 1.4f0.2 306f 22 
Y203A 0.6fO.l 98f 1 
Y213A 0.5fO.l 540f 41 
C306A 0.3 f 0.04 366+ 90 
S318A 1.8kO.3 390f 24 


















































8.4 223 0.71 
64 476 0.62 
11 173 0.59 
9.8 249 0.52 
3.7 100 0.66 
- _ 2 
_ _ 4 
_ _ 1.1 
_ _ _ 
- - 3 
- - 1.1 
_ _ 1.6 
- - 0.82 
_ _ 1.1 
_ _ 0.78 
- - 1.2 
_ _ 49 
Receptor expression was assessed measuring the binding of 250 pM [iz51]HEAT on membranes from cells expressing the various receptors. 
The ICss of (-)-epinephrine ((-)-EPI), (+)-epinephrine ((+)-EPI), (-)-norepinephrine ((-)-NE), phenylephrine (PHE), synephrine (SYN) and 
prazosin (PRA) were assessed in competition binding experiments using 80 pM [iz51]HEAT. 
R,, indicates the EPI-induced accumulation of total inositol phosphates (IP) expressed as % increase above basal levels in the absence of EPI. 
Results concerning the expression and IP mesurements are the mean f SE of independent experiments for the WT (n = 9) and mutant (n = 3) 
receptors. The I& values were from 2-3 experiments which agreed within 20%. The ligand binding properties of the S135A mutant were not 
assessed because of its low expression level. 
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ing. Thus, C306 seems to play a structural role in the a1n-AR, 
consistently with the finding that the C306A mutant displys 
lower expression levels as compared to the wild-type receptor. 
Finally, an important structural role is played by the highly 
conserved Y338 in TMDVII. This residue is not directly in- 
volved in agonist binding despite the fact that its mutation has 
profound effects on ligand binding as in the Y338A receptor 
mutant. In particular, Y338 is directed towards TMDII inter- 
acting with S102. Thus, the integrity of Y338 is important to 
maintain the receptor sructure and thus, indirectly, preserving 
the ligand binding properties of the am-AR. 
4. Conclusions 
The binding site of catecholamines in the am-AR had not 
been previously defined in great detail [15]. In our study, the 
combination of mutational and structural/dynamical analysis 
of the am-AR provides new informations about both the 
inter- and intramolecular interactions characterizing the (-)- 
epinephrine-amAR complex. Our analysis provides solid evi- 
dence that D125 in TMDIII interacts with the amino group of 
both agonists and antagonists, whereas S207 in TMDV inter- 
acts with both catecholic hydroxy-groups of (-)-epinephrine. 
In addition, our results identify a large number of polar res- 
idues playing an important role in the activation process of 
the am-AR, thus providing new insights into the structure/ 
function relationship of GPCR. 
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